NCT05893498

Brief Summary

To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.

Trial Health

62
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,924

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2023

Typical duration for not_applicable

Geographic Reach
5 countries

59 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 8, 2023

Completed
13 days until next milestone

Study Start

First participant enrolled

June 21, 2023

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

March 10, 2026

Status Verified

March 1, 2026

Enrollment Period

2.9 years

First QC Date

April 25, 2023

Last Update Submit

March 9, 2026

Conditions

Keywords

PCICoronary Artery DiseaseFFRangioPressure Wire-Guided

Outcome Measures

Primary Outcomes (1)

  • MACE

    Rate of the composite of all-cause death, myocardial infarction (MI) or unplanned clinically-driven revascularization

    1 year

Secondary Outcomes (17)

  • All-Cause Mortality

    12 months

  • Myocardial Infarction

    12 months

  • Unplanned Revascularization

    12 months

  • Stent thrombosis

    12 months

  • Peri-Procedural Complications

    30 Days

  • +12 more secondary outcomes

Study Arms (2)

FFRangio

EXPERIMENTAL

FFRangio guided revascularization

Device: FFRangio

Pressure wire

ACTIVE COMPARATOR

Pressure wire-based guided revascularization (FFR or NHPR)

Device: FFR or NHPR

Interventions

FFRangioDEVICE

A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.

FFRangio

Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).

Also known as: FFR, iFR RFR, dPR, Pd/Pa
Pressure wire

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \. Adult patients (≥18 years of age) with one or more study lesion(s) (diameter stenosis 50-90%) deemed appropriate for both pressure-wire and FFRangio physiologic assessment.

You may not qualify if:

  • Subject with ST-elevation (MI (STEMI) within 72 hours at time of study enrollment
  • Prior coronary artery bypass graft (CABG) with patent grafts to the study vessel(s)
  • Patients undergoing coronary physiologic assessment where one possible outcome is referral for CABG
  • The study vessel supplies a significant nonviable territory (e.g., prior transmural MI)
  • Severe left sided valvular heart disease
  • Most recent documented LVEF ≤30%
  • Women who are pregnant or breastfeeding (women of childbearing potential are required to have negative pregnancy test within 1 week of index procedure)
  • Patients with life expectancy \<1 year life as estimated by treating physician.
  • Subjects enrolled in other ongoing non-registry clinical studies that would impact conduct or outcomes of this study (registries and long-term follow-up of other studies are allowed)
  • Subjects who have undergone angiographic or wire-based coronary physiological assessment for 1 or more potential study lesions within 30 days of enrollment.
  • Coronary angiogram is not acquired per instructions as defined in the Study Protocol
  • Sthe study lesion is the clear culprit for a NSTEACS
  • Angiographic evidence of a procedural complication (e.g., acute stent thrombosis, flow-limiting dissection, perforation, slow/no reflow, or other) prior to randomization
  • Thrombolysis in myocardial infarction (TIMI) Grade 2 flow or lower in any study vessel at time of enrollment
  • The study vessel is in a left coronary vessel with separate left anterior descending and left circumflex ostia arising from the aorta
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (59)

University of California San Diego Health

La Jolla, California, 92037, United States

Location

VA- Long Beach Healthcare

Long Beach, California, 90822, United States

Location

Keck Medicine of USC

Los Angeles, California, 90033, United States

Location

UCLA Medical Center

Los Angeles, California, 90095, United States

Location

Stanford University

Palo Alto, California, 94305, United States

Location

VA - Palo Alto Healthcare

Palo Alto, California, 94305, United States

Location

Kaiser Permanente San Francisco

San Francisco, California, 94118, United States

Location

St. Joesph's Medical Center

Stockton, California, 95204, United States

Location

HCA Florida JFK Hospital

Atlantis, Florida, 33462, United States

Location

Cardiac & Vascular Institute

Gainesville, Florida, 32605, United States

Location

University of Miami

Miami, Florida, 33136, United States

Location

HCA Florida Northside Hospital

St. Petersburg, Florida, 33709, United States

Location

Tallahassee Research Institute

Tallahassee, Florida, 32308, United States

Location

University of South Florida

Tampa, Florida, 33606, United States

Location

Archbold Hospital

Thomasville, Georgia, 31792, United States

Location

Carle Foundation Hospital

Urbana, Illinois, 61801, United States

Location

Ascension Via Christi St. Francis

Wichita, Kansas, 67214, United States

Location

Kansas Heart Hospital

Wichita, Kansas, 67226, United States

Location

St. Elizabeth Healthcare

Edgewood, Kentucky, 41017, United States

Location

Medstar Union Memorial Hospital

Baltimore, Maryland, 21218, United States

Location

TidalHealth, INC

Salisbury, Maryland, 21801, United States

Location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

Ascension St. John Hospital

Detroit, Michigan, 48236, United States

Location

Metropolitan Heart Vascular Institute

Coon Rapids, Minnesota, 55433, United States

Location

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, 55407, United States

Location

Cardiac Associates Research

Tupelo, Mississippi, 38801, United States

Location

Mountainside Medical Center

Montclair, New Jersey, 07042, United States

Location

Morristown Medical Center

Morristown, New Jersey, 07960, United States

Location

The Valley Hospital

Ridgewood, New Jersey, 07450, United States

Location

New York Presbyterian Methodist Hospital

Brooklyn, New York, 11215, United States

Location

NYU Langone Health

New York, New York, 10016, United States

Location

Columbia University Medical Center / New York Presbyterian Hospital

New York, New York, 10032, United States

Location

New York Presbyterian / Weill Cornell Medical Center

New York, New York, 10065, United States

Location

Northwell Health (Lenox Hill, North Shore, South Shore, Huntington, Staten Island))

New York, New York, 10075, United States

Location

St. Francis Hospital and Heart Center

Roslyn, New York, 11576, United States

Location

Ellis Hospital

Schenectady, New York, 12308, United States

Location

The Christ Hospital

Cincinnati, Ohio, 45219, United States

Location

Mount Carmel Health System

Columbus, Ohio, 43219, United States

Location

Lehigh Valley Health

Allentown, Pennsylvania, 18103, United States

Location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Baylor Scott & White The Heart Hospital - Plano

Plano, Texas, 75093, United States

Location

HCA Methodist Healthcare of San Antonio

San Antonio, Texas, 78249, United States

Location

Inova Fairfax Hospital

Fairfax, Virginia, 22031, United States

Location

Golda HaSharon Hospital

Petah Tikva, 49372, Israel

Location

Rabin Medical Centre

Petah Tikva, 4941492, Israel

Location

Fukuyama Cardiovascular Hospital

Fukuyama, Japan

Location

Gifu Heart Center

Gifu, Japan

Location

Ichinomiyanishi Hospital

Ichinomiya, Japan

Location

Kobe University

Kobe, Japan

Location

Chibanishi General Hospital

Matsudo, Japan

Location

Mie University Hospital

Osaka, Japan

Location

NTT Medical Center Tokyo

Tokyo, Japan

Location

Sakakibara Heart Institute

Tokyo, Japan

Location

Hopitaux Universitaires Geneve (HUG)

Geneva, Switzerland

Location

centre hospitalier universitaire vaudois (CHUV)

Lausanne, CH-1011, Switzerland

Location

Hôpital Cantonal de Fribourg (HFR)

Villars-sur-Glâne, Switzerland

Location

Basildon University Hospital

Basildon, United Kingdom

Location

Imperial College Healthcare

London, W12 0HS, United Kingdom

Location

Musgrove Park Hospital

Taunton, United Kingdom

Location

Related Publications (2)

  • Fearon WF, Jeremias A, Witberg G, Al-Lamee R, Cohen DJ, Kaki A, Sharma RP, Yeh RW, Chehab BM, Kim MC, Otake H, Tayal R, Matsuo H, McEntegart M, Patel AK, Sandoval Y, Al-Azizi KM, Dan K, Razzouk L, Fournier S, Popma A, Popma JJ, Zhao D, Redfors B, Madhavan MV, Kornowski R, Leon MB, Kirtane AJ; ALL-RISE Investigators. Angiography-Derived Fractional Flow Reserve to Guide PCI. N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2600949. Online ahead of print.

  • Redfors B, Madhavan MV, Kirtane AJ, Fearon WF, Yeh RW, Cohen DJ, Al-Lamee R, Jeremias A, Witberg G, Sharma RP, Popma A, Kaki A, Froimovich A, Leon MB. FFRangio-guided versus pressure wire-guided PCI: design and rationale of the multicentre, randomised ALL-RISE trial. EuroIntervention. 2025 Aug 18;21(16):961-969. doi: 10.4244/EIJ-D-25-00200.

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Ajay J Kirtane, MD, SM

    NewYork-Presbyterian/Columbia University Irving Medical Center

    STUDY CHAIR
  • William F Fearon, MD

    Stanford University

    PRINCIPAL INVESTIGATOR
  • Allen Jeremias, MD, MSc

    St. Francis Hospital & Heart Center

    PRINCIPAL INVESTIGATOR
  • Martin B Leon, MD

    NewYork-Presbyterian/Columbia University Irving Medical Center

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2023

First Posted

June 8, 2023

Study Start

June 21, 2023

Primary Completion

May 1, 2026

Study Completion

May 1, 2026

Last Updated

March 10, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations